12/20
04:05 pm
gild
Gilead Sciences to Present at Upcoming Investor Conference
Low
Report
Gilead Sciences to Present at Upcoming Investor Conference
12/19
07:11 pm
gild
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know [Yahoo! Finance]
Low
Report
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know [Yahoo! Finance]
12/18
08:05 pm
gild
Lightning Round: Uber is attractive at these levels, says Jim Cramer [CNBC]
Low
Report
Lightning Round: Uber is attractive at these levels, says Jim Cramer [CNBC]
12/18
11:52 am
gild
GILD Signs Collaboration Agreement With Terray Therapeutics [Yahoo! Finance]
Low
Report
GILD Signs Collaboration Agreement With Terray Therapeutics [Yahoo! Finance]
12/18
10:52 am
gild
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains [Yahoo! Finance]
12/17
08:45 am
gild
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer [Yahoo! Finance]
12/17
08:30 am
gild
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Low
Report
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
12/17
07:11 am
gild
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies [Yahoo! Finance]
Low
Report
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies [Yahoo! Finance]
12/17
07:00 am
gild
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Low
Report
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
12/16
03:22 pm
gild
GILD Obtains Positive CHMP Opinion for Liver Disease Drug [Yahoo! Finance]
Low
Report
GILD Obtains Positive CHMP Opinion for Liver Disease Drug [Yahoo! Finance]
12/16
01:22 pm
gild
Gilead (GILD) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
Gilead (GILD) Upgraded to Buy: Here's Why [Yahoo! Finance]
12/13
07:34 pm
gild
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know [Yahoo! Finance]
Low
Report
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know [Yahoo! Finance]
12/13
06:37 am
gild
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Low
Report
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
12/12
05:30 pm
gild
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Low
Report
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
12/11
11:58 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $80.00 price target on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $80.00 price target on the stock.
12/11
10:48 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $84.00 price target on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $84.00 price target on the stock.
12/10
08:01 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $105.00 to $115.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $105.00 to $115.00. They now have an "outperform" rating on the stock.
12/10
08:00 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $109.00 price target on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $109.00 price target on the stock.
12/9
05:51 pm
gild
Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 [Yahoo! Finance]
Low
Report
Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 [Yahoo! Finance]
12/9
05:45 pm
gild
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
Low
Report
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
12/9
04:30 pm
gild
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Low
Report
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
12/8
12:34 pm
gild
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH [Yahoo! Finance]
Low
Report
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH [Yahoo! Finance]
12/8
12:30 pm
gild
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
Low
Report
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
12/7
05:54 pm
gild
Baltimore City declares Dec.1 Carlton Smith Day in honor of HIV activist's legacy [CBS News]
Low
Report
Baltimore City declares Dec.1 Carlton Smith Day in honor of HIV activist's legacy [CBS News]
12/4
11:28 am
gild
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC [Yahoo! Finance]
Low
Report
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC [Yahoo! Finance]